The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...
This Peninsula biotech company started as a way to find a cancer drug for a co-founder's father. It now layoffs show it’s ...
According to US secondary stroke prevention guidelines, patients with ESUS should not be treated with anticoagulants or ...
Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...
On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer ...
By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Sept 18 (Reuters ...
R&D image Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, ...
Ioannis Sapountzis, head of global therapeutic areas at Boehringer, said that FIBRONEER-IPF is the largest trial in IPF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback